查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403491

2030 年癌症干细胞治疗市场预测：按癌症类型、治疗类型、最终用户和地区进行的全球分析

Cancer Stem Cells Therapy Market Forecasts to 2030 - Global Analysis By Cancer Type, Therapeutic Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球癌症干细胞治疗市场规模将达49亿美元，预计2030年将达到111亿美元，预测期内复合年增长率为12.2%。

癌症干细胞治疗涉及针对癌症干细胞（CSC）的治疗策略的开发和实施。 CSC 是肿瘤内的一群细胞，被认为具有自我更新和分化潜力。这些细胞参与肿瘤的发生、进展和抗治疗性。癌症干细胞疗法旨在根除或抑制这些细胞的生长，从而解决癌症的根本原因并防止復发。

据世界卫生组织(WHO)称，癌症是全球第一大死因，到2020年将导致约1,000万人死亡。

个人化医疗的重要性日益增加

影响癌症进展的分子和遗传因素的复杂性导致了基于个别患者特征定制治疗方法的范式转变。每种癌症干细胞都具有独特的分子特征，在肿瘤的发展和復发中发挥关键作用。对个人化医疗的重视与针对特定细胞成分的目标无缝结合，从而实现更精确和有效的治疗性介入。此外，根据每位患者独特的基因组成客製化癌症干细胞疗法揭示了改善治疗结果和减少副作用的潜力。

开发成本高

癌症干细胞研究的复杂性，加上临床试验和药物核准的严格监管要求，需要大量资金。阐明癌症干细胞的复杂特性、进行临床前测试并经历严格的临床试验阶段所需的广泛研究增加了开发成本。此外，与这些治疗方法的成功和商业性潜力相关的不确定性进一步增加了财务风险。製药公司和研究机构面临着平衡技术创新需求与将新型癌症干细胞疗法推向市场的财务负担的挑战。

增加对癌症研究的投资

随着对癌症生物学认识的进步，人们已经认识到癌症干细胞在肿瘤的发生和进展中发挥关键作用。这种认知导致公共和私营部门的研究经费激增，以揭示癌症干细胞的复杂性并开发标靶治疗。人们越来越注重识别创新治疗方法和推动肿瘤学科学知识，这正在创造一个有利于新型癌症干细胞治疗方法出现的环境。

道德和监管问题

干细胞研究（包括胚胎干细胞）的复杂性引发了有关治疗细胞来源和起源的伦理问题。这导致了持续的争论，有时甚至是监管限制，阻碍了某些基于干细胞的治疗方法的开发和接受。此外，临床试验和治疗方法核准的严格法律规范也加剧了研究人员和开发人员在将癌症干细胞治疗方法推向市场时所面临的挑战。

COVID-19 的影响：

这场危机凸显了对创新治疗方法的迫切需求，包括针对癌症干细胞的创新疗法，而研究活动、临床试验和医疗保健服务的中断正在阻碍市场轨迹。由于资源被转移到与大流行相关的工作、临床试验时间表的推迟以及患者招募方面的挑战，癌症干细胞治疗的发展速度已经放缓。此外，经济不确定性和医疗保健优先事项的变化正在影响该领域的资金筹措和投资模式。

乳癌干细胞治疗领域预计在预测期内规模最大

乳癌干细胞治疗领域由于其从根源治疗乳癌的针对性方法，在预测期内占据了最大的市场份额。针对这些特定细胞的治疗可提供更有效和持久的治疗结果，并减少癌症復发的机会。这种针对癌症干细胞的精确性提高了治疗的整体疗效，并有助于增加市场采用和需求。此外，在阐明乳癌干细胞分子机制方面的持续研究和进展正在进一步支持创新治疗方法的开发、吸引投资并推动市场扩张。

预计基因治疗领域在预测期内的复合年增长率最高。

由于先进的基因技术特异性针对和修改癌症干细胞，预计基因治疗领域将在预测期内出现良好的成长。基因疗法允许引入治疗基因或操纵现有基因来破坏对癌症干细胞的生存和增殖至关重要的信号途径。此外，这种创新方法不仅提高了癌症治疗的精确度，而且最大限度地减少了对正常细胞的损害并减少了副作用。

比最大的地区

由于乳癌、肺癌和大肠等癌症的发生率特别高，亚太地区在估计期间占据了最大的市场占有率。这种高疾病负担正在刺激对先进医学研究和治疗的投资增加，创造有利于扩大癌症干细胞治疗的环境。此外，亚太地区医疗保健领域正在经历快速的技术进步和创新，促进了尖端治疗方法的开发，包括针对癌症干细胞的治疗方法。

复合年增长率最高的地区：

亚太地区注重研发，加上生物技术和製药行业的快速增长，为发现特异性针对癌症干细胞的新治疗方法并提高治疗效果铺平了道路，因此，预计快速增长。因此，在对更精确和客製化治疗的需求的推动下，癌症干细胞治疗方法的采用显着增加。此外，该地区政府和监管机构正在积极支持医疗基础设施、研究计划和临床试验的进步，创造一个新疗法能够快速融入癌症治疗主流的环境。我正在安排。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球癌症干细胞治疗市场：依癌症类型

  • 脑肿瘤干细胞治疗
  • 乳癌干细胞治疗
  • 大肠直肠癌干细胞治疗
  • 肺癌干细胞治疗
  • 摄护腺癌干细胞治疗
  • 其他癌症类型

第六章全球癌症干细胞治疗市场：依治疗类型

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 干细胞移植
  • 标靶治疗
  • 分化治疗
  • 基因治疗
  • 基于奈米粒子的治疗方法
  • 联合治疗
  • 其他治疗类型

第七章全球癌症干细胞治疗市场：依最终用户分类

  • 癌症研究
  • 医院
  • 专科诊所
  • 学术医疗中心
  • 专业医护人员
    • 外科医生
    • 放射肿瘤科医生
    • 血液学家
  • 其他最终用户

第八章全球癌症干细胞治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • AbbVie Inc.
  • AdnaGen AG
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • Cancer Stem Cells Co., Ltd
  • Gamida Cells
  • Glycosyn LLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novadip Biosciences
  • Novartis AG
  • OncoMed Pharmaceuticals
  • Pfizer Inc
  • Roche Holdings AG
  • Stemline Therapeutics, Inc.
  • Thermo Fisher Scientific, Inc
Product Code: SMRC24716

According to Stratistics MRC, the Global Cancer Stem Cells Therapy Market is accounted for $4.9 billion in 2023 and is expected to reach $11.1 billion by 2030 growing at a CAGR of 12.2% during the forecast period. The Cancer Stem Cells Therapy involves the development and implementation of therapeutic strategies specifically targeting cancer stem cells (CSCs), a subpopulation of cells within tumors believed to possess self-renewal and differentiation capabilities. These cells are implicated in tumor initiation, progression, and treatment resistance. Cancer stem cell therapy aims to eradicate or inhibit the growth of these cells, thereby addressing the root cause of cancer and preventing relapse.

According to World Health Organization (WHO), cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

Market Dynamics:

Driver:

Growing emphasis on personalized medicine

Due to the intricate molecular and genetic factors influencing cancer advances, there is a paradigm shift towards tailoring treatments based on individual patient characteristics. Cancer stem cells, with their distinct molecular profiles, play a pivotal role in tumor development and recurrence. The emphasis on personalized medicine aligns seamlessly with the objective of targeting these specific cellular components, allowing for more precise and effective therapeutic interventions. Additionally, by customizing cancer stem cell therapies to the unique genetic makeup of each patient, the potential for improved treatment outcomes and reduced side effects becomes apparent.

Restraint:

High development costs

The intricate nature of cancer stem cell research, coupled with the stringent regulatory requirements for clinical trials and drug approvals, contributes to substantial financial investments. The extensive research needed to unravel the complexities of cancer stem cells, conduct preclinical studies, and progress through rigorous clinical trial phases amplifies development expenses. Moreover, the uncertainty associated with the success and commercial viability of these therapies adds to the financial risk. Pharmaceutical companies and research institutions face the challenge of balancing the imperative to innovate with the financial burden of bringing novel cancer stem cell therapies to market.

Opportunity:

Increasing investment in oncology research

As the understanding of cancer biology evolves, there is a growing recognition of the pivotal role played by cancer stem cells in tumor initiation and progression. This realization has prompted a surge in research funding, both from public and private sectors, dedicated to unraveling the complexities of cancer stem cells and developing targeted therapies. The heightened focus on identifying innovative treatment modalities and advancing scientific knowledge in oncology creates a conducive environment for the emergence of novel cancer stem cell therapies.

Threat:

Ethical and regulatory concerns

The intricate nature of stem cell research, including the use of embryonic stem cells, raises ethical considerations surrounding the source and derivation of cells for therapy. This has prompted ongoing debates and, at times, regulatory restrictions, creating hurdles in the development and acceptance of certain stem cell-based treatments. Additionally, stringent regulatory frameworks governing clinical trials and therapeutic approvals contribute to the challenges faced by researchers and developers in bringing cancer stem cell therapies to market.

COVID-19 Impact:

While the crisis emphasized the urgent need for innovative therapies, including those targeting cancer stem cells, disruptions in research activities, clinical trials, and healthcare services have impeded the market's trajectory. The redirection of resources toward pandemic-related efforts, delays in clinical trial timelines, and challenges in patient recruitment have slowed down the pace of cancer stem cell therapy development. Additionally, economic uncertainties and shifts in healthcare priorities have influenced funding availability and investment patterns in the sector.

The breast cancer stem cells therapy segment is expected to be the largest during the forecast period

Breast Cancer Stem Cells Therapy segment dominated the largest share of the market over the forecast period due to its targeted approach in treating breast cancer at its roots. The therapeutic focus on these specific cells allows for more effective and sustained treatment outcomes, reducing the likelihood of cancer relapse. This precision in targeting cancer stem cells enhances the overall efficacy of therapies, contributing to increased adoption and demand in the market. Additionally, ongoing research and advancements in understanding the molecular mechanisms of breast cancer stem cells further fuel the development of innovative therapies, attracting investments and driving market expansion.

The gene therapy segment is expected to have the highest CAGR during the forecast period

Gene Therapy segment is estimated to witness lucrative growth over the projection period due to the advanced genetic techniques to specifically target and modify cancer stem cells. Gene therapy enables the introduction of therapeutic genes or the manipulation of existing ones to disrupt the signaling pathways crucial for the survival and proliferation of cancer stem cells. Furthermore, this innovative approach not only enhances the precision of cancer treatment but also minimizes damage to normal cells, reducing side effects.

Region with largest share:

Asia Pacific region commanded the largest market share over the extrapolated period due to a surge in cancer incidence, with breast, lung, and colorectal cancers being particularly prevalent. This high disease burden has spurred increased investments in advanced medical research and treatment modalities, creating a conducive environment for the expansion of cancer stem cell therapies. Moreover, the Asia Pacific region has experienced rapid technological advancements and innovation in the healthcare sector, fostering the development of cutting-edge therapies, including those targeting cancer stem cells.

Region with highest CAGR:

Asia Pacific region is projected to grow at a rapid pace owing to a strong focus on research and development, coupled with a burgeoning biotechnology and pharmaceutical industry, has paved the way for the discovery of novel therapeutic approaches that specifically target cancer stem cells, enhancing treatment efficacy. As a result, there is a notable increase in the adoption of cancer stem cell therapies, driven by the demand for more precise and tailored treatment options. Additionally, governments and regulatory bodies in the region are also actively supporting advancements in healthcare infrastructure, research initiatives, and clinical trials, creating an environment conducive to the rapid integration of novel therapies into mainstream cancer care.

Key players in the market:

Some of the key players in Cancer Stem Cells Therapy market include AbbVie Inc., AdnaGen AG, Astellas Pharma Inc., Bristol Myers Squibb, Cancer Stem Cells Co., Ltd, Gamida Cells, Glycosyn LLC, Johnson & Johnson, Merck & Co., Inc., Novadip Biosciences, Novartis AG, OncoMed Pharmaceuticals, Pfizer Inc, Roche Holdings AG, Stemline Therapeutics, Inc. and Thermo Fisher Scientific, Inc.

Key Developments:

In December 2023, Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH. Significant unmet need remains in PNH, a chronic and rare blood disorder; despite anti-C5 therapy, a large proportion of patients can remain anemic and dependent on blood transfusions

In July 2023, US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease. Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart disease

Cancer Types Covered:

  • Brain Cancer Stem Cells Therapy
  • Breast Cancer Stem Cells Therapy
  • Colorectal Cancer Stem Cells Therapy
  • Lung Cancer Stem Cells Therapy
  • Prostate Cancer Stem Cells Therapy
  • Other Cancer Types

Therapeutic Types Covered:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • Targeted Therapy
  • Differentiation Therapy
  • Gene Therapy
  • Nanoparticle-Based Therapies
  • Combination Therapies
  • Other Therapeutic Types

End Users Covered:

  • Cancer Research Institutes
  • Hospitals
  • Specialty Clinics
  • Academic Medical Centers
  • Healthcare Professionals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Stem Cells Therapy Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Brain Cancer Stem Cells Therapy
  • 5.3 Breast Cancer Stem Cells Therapy
  • 5.4 Colorectal Cancer Stem Cells Therapy
  • 5.5 Lung Cancer Stem Cells Therapy
  • 5.6 Prostate Cancer Stem Cells Therapy
  • 5.7 Other Cancer Types

6 Global Cancer Stem Cells Therapy Market, By Therapeutic Type

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Immunotherapy
  • 6.4 Radiation Therapy
  • 6.5 Stem Cell Transplantation
  • 6.6 Targeted Therapy
  • 6.7 Differentiation Therapy
  • 6.8 Gene Therapy
  • 6.9 Nanoparticle-Based Therapies
  • 6.10 Combination Therapies
  • 6.11 Other Therapeutic Types

7 Global Cancer Stem Cells Therapy Market, By End User

  • 7.1 Introduction
  • 7.2 Cancer Research Institutes
  • 7.3 Hospitals
  • 7.4 Specialty Clinics
  • 7.5 Academic Medical Centers
  • 7.6 Healthcare Professionals
    • 7.6.1 Surgeons
    • 7.6.2 Radiation Oncologists
    • 7.6.3 Hematologists
  • 7.7 Other End Users

8 Global Cancer Stem Cells Therapy Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AbbVie Inc.
  • 10.2 AdnaGen AG
  • 10.3 Astellas Pharma Inc.
  • 10.4 Bristol Myers Squibb
  • 10.5 Cancer Stem Cells Co., Ltd
  • 10.6 Gamida Cells
  • 10.7 Glycosyn LLC
  • 10.8 Johnson & Johnson
  • 10.9 Merck & Co., Inc.
  • 10.10 Novadip Biosciences
  • 10.11 Novartis AG
  • 10.12 OncoMed Pharmaceuticals
  • 10.13 Pfizer Inc
  • 10.14 Roche Holdings AG
  • 10.15 Stemline Therapeutics, Inc.
  • 10.16 Thermo Fisher Scientific, Inc

List of Tables

  • Table 1 Global Cancer Stem Cells Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Stem Cells Therapy Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Cancer Stem Cells Therapy Market Outlook, By Brain Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 4 Global Cancer Stem Cells Therapy Market Outlook, By Breast Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 5 Global Cancer Stem Cells Therapy Market Outlook, By Colorectal Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 6 Global Cancer Stem Cells Therapy Market Outlook, By Lung Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 7 Global Cancer Stem Cells Therapy Market Outlook, By Prostate Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 8 Global Cancer Stem Cells Therapy Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 9 Global Cancer Stem Cells Therapy Market Outlook, By Therapeutic Type (2021-2030) ($MN)
  • Table 10 Global Cancer Stem Cells Therapy Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 11 Global Cancer Stem Cells Therapy Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 12 Global Cancer Stem Cells Therapy Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 13 Global Cancer Stem Cells Therapy Market Outlook, By Stem Cell Transplantation (2021-2030) ($MN)
  • Table 14 Global Cancer Stem Cells Therapy Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 15 Global Cancer Stem Cells Therapy Market Outlook, By Differentiation Therapy (2021-2030) ($MN)
  • Table 16 Global Cancer Stem Cells Therapy Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 17 Global Cancer Stem Cells Therapy Market Outlook, By Nanoparticle-Based Therapies (2021-2030) ($MN)
  • Table 18 Global Cancer Stem Cells Therapy Market Outlook, By Combination Therapies (2021-2030) ($MN)
  • Table 19 Global Cancer Stem Cells Therapy Market Outlook, By Other Therapeutic Types (2021-2030) ($MN)
  • Table 20 Global Cancer Stem Cells Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Cancer Stem Cells Therapy Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 22 Global Cancer Stem Cells Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Cancer Stem Cells Therapy Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 24 Global Cancer Stem Cells Therapy Market Outlook, By Academic Medical Centers (2021-2030) ($MN)
  • Table 25 Global Cancer Stem Cells Therapy Market Outlook, By Healthcare Professionals (2021-2030) ($MN)
  • Table 26 Global Cancer Stem Cells Therapy Market Outlook, By Surgeons (2021-2030) ($MN)
  • Table 27 Global Cancer Stem Cells Therapy Market Outlook, By Radiation Oncologists (2021-2030) ($MN)
  • Table 28 Global Cancer Stem Cells Therapy Market Outlook, By Hematologists (2021-2030) ($MN)
  • Table 29 Global Cancer Stem Cells Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.